Professor Sarah Parish
BSc, MSc, DPhil
Professor of Medical Statistics and Epidemiology
- MRC Programme Leader
Sarah Parish studied Mathematics at Bristol and Oxford Universities and joined the unit which became CTSU (and is now part of NDPH) in 1978. She has played a major role as a statistician in the establishment, conduct and interpretation of CTSU’s series of ground-breaking large-scale randomised trials in the treatment and prevention of cardiovascular disease. She has also been active in developing large-scale blood-based observational studies with extensive biomarker panels and genotyping. As the Director of Statistics in Vascular Trials and Genetic Epidemiology, she now leads statistical teams engaged in a spectrum of complimentary research. Her particular interests include: identifying genetic risk factors for the side-effects of common cardiovascular treatments; investigating causality in relation to factors such as adiposity and dementia that are responsible for major burdens of disease, using the large UK and China Kadoorie biobanks.
Investigating modifications to participant information materials to improve recruitment into a large randomized trial.
HPS2-THRIVE Collaborative Group None. et al, (2019), Trials, 20
Effects of omega−3 fatty acid supplements on arrhythmias
PARISH S. et al, (2019), Circulation
Impact of history of vascular disease on lipoprotein(a) associations with cardiovascular outcomes: a Mendelian randomisation study in 283,658 UK Biobank participants
Stiby A. et al, (2019), EUROPEAN HEART JOURNAL, 40, 684 - 684
Risk of major gastrointestinal bleed in relation to vascular disease risk in 0.5M UK Biobank participants
Hammami I. et al, (2019), EUROPEAN HEART JOURNAL, 40, 265 - 265
Serious Adverse Effects of Extended-Release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R. et al, (2019), Clin Ther